Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Allogene Therapeutics, Inc. - Common Stock
(NQ:
ALLO
)
1.340
-0.030 (-2.19%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 2, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Allogene Therapeutics, Inc. - Common Stock
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Why Everbridge Jumped Over 17%; Here Are 90 Biggest Movers From Friday
↗
August 29, 2022
Gainers Micro Focus International plc (NYSE: MFGP) shares surged 92% to close at $6.01 on Friday after the company reached an agreement with OpenText to be acquired for $6 billion.
Via
Benzinga
What 5 Analyst Ratings Have To Say About Allogene Therapeutics
↗
August 10, 2022
Over the past 3 months, 5 analysts have published their opinion on Allogene Therapeutics (NASDAQ:ALLO) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2022
↗
August 10, 2022
Via
Benzinga
Allogene Therapeutics: Q2 Earnings Insights
↗
August 09, 2022
Allogene Therapeutics (NASDAQ:ALLO) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Allogene Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
July 27, 2022
Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Beyond Meat, Canoo, Veru And More: 12 Short Squeeze Candidates To Watch
↗
July 20, 2022
One of the most powerful tradable market events is a short squeeze, so traders are always on the lookout for the next short squeeze candidate. S3 Partners analyst Ihor Dusaniwsky has just released a...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 15, 2022
↗
July 15, 2022
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
July 15, 2022
Via
Benzinga
89 Biggest Movers From Friday
↗
June 21, 2022
Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022
↗
June 03, 2022
Via
Benzinga
What 4 Analyst Ratings Have To Say About Allogene Therapeutics
↗
June 03, 2022
Analysts have provided the following ratings for Allogene Therapeutics (NASDAQ:ALLO) within the last quarter:
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
May 17, 2022
Via
Benzinga
Why This Analyst Has 'Little Conviction' On CRISPR's Upcoming Trial Data
↗
May 10, 2022
Via
Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
↗
May 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
U.S. FDA Grants Orphan-Drug Designation for Allogene's ALLO-605 for multiple myeloma
↗
April 27, 2022
Allogene Therapeutics, Inc. (Nasdaq: ALLO) received Orphan-drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for its drug candidate ALLO-605 for the treatment of patients with...
Via
Benzinga
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
↗
April 27, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Global Antibiotic Resistance Market to Hit US$16.5 Billion By 2030
April 21, 2022
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 21, 2022 – Resistance to antibiotics is a growing concern. About 750,000 people die each year worldwide from...
Via
FinancialNewsMedia
Allogene's Preclinical Data Show Healthy Donor-Derived Allogeneic CAR T Cells Have Better Immune Fitness, Killing Activity
↗
March 23, 2022
Allogene Therapeutics Inc (NASDAQ: ALLO) announced the
Via
Benzinga
Recap: Allogene Therapeutics Q4 Earnings
↗
February 23, 2022
Allogene Therapeutics (NASDAQ:ALLO) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:00 PM. Here's what investors need to know about the announcement....
Via
Benzinga
Allogene Therapeutics Earnings Preview
↗
February 22, 2022
Allogene Therapeutics (NASDAQ:ALLO) is set to give its latest quarterly earnings report on Wednesday, 2022-02-23. Here's what investors need to know before the announcement....
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
↗
February 16, 2022
On Wednesday, 115 companies reached new 52-week lows. Noteworthy Points From Today's 52-Week Lows: The largest company by market cap to hit a new 52-week low...
Via
Benzinga
FDA Lifts Clinical Hold On Allogene's CAR-T Trials
↗
January 11, 2022
The FDA has lifted the hold on Cellectis SA's (NASDAQ: CLLS) licensed partner, Allogene Therapeutics Inc (NASDAQ: ALLO) clinical trials. The...
Via
Benzinga
Biotech Bloodbath Continues Despite Gene-Editing Deals For Pfizer, Bayer
↗
January 10, 2022
Pfizer and Bayer inked deals with several companies in gene-editing.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
December 20, 2021
Gainers Intra-Cellular Therapies (NASDAQ:ITCI) stock rose 18.79% to $46.52 during Monday's pre-market session. The market value of their outstanding shares is at $3.7...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
↗
December 13, 2021
Gainers Arena Pharmaceuticals (NASDAQ:ARNA...
Via
Benzinga
58 Biggest Movers From Yesterday
↗
December 14, 2021
Gainers Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) shares jumped 80.4% to close at $90.08 on Monday. Pfizer agreed to acquire Arena Pharmaceuticals for $100 per share in an all-...
Via
Benzinga
The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More
↗
December 12, 2021
Biotech stocks closed out the week ending Dec. 10 with modest losses as investors moved money out of defensives and into risky bets amid the broader market rebound. Multiple...
Via
Benzinga
Being First Is Not Enough For Crispr Therapeutics
↗
November 15, 2021
CRSP stock is facing competition and meeting skepticism as the company tries to turn CRISPR-CAS9 into profitable drug therapies.
Via
InvestorPlace
Allogene Therapeutics Inc (ALLO) Q3 2021 Earnings Call Transcript
↗
November 05, 2021
ALLO earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
↗
November 04, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &...
Via
Benzinga
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
